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Abstract
Manystudies have shown thatmicroRNA expression incancer maybe regulatedby epigenetic events. Recently, we foundthat
in lung cancer miR-212 was strongly down-regulated. However, mechanisms involved in the regulation of miR-212 expression
are unknown. Therefore, we addressed this point by investigating the molecular mechanisms of miR-212 silencing in lung
cancer. We identified histone modifications rather than DNA hypermethylation as epigenetic events that regulate miR-212
levels in NSCLC. Moreover, we found that miR-212 silencing in vivo is closely associated with the severity of the disease.
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Introduction
Worldwide, lung cancer is the most common cancer in terms of
both incidence and mortality (1.35 million new cases per year and
1.18 million deaths), with the highest rates in Europe and North
America. The main types of lung cancer are small cell lung carcinoma
(SCLC) and non-small cell lung carcinoma (NSCLC). The non-small
cell lung carcinomas include adenocarcinomas, squamous cell lung
carcinomas, and large cell lung carcinomas. These tumors have
only a 20–30% positive clinical response, however the cause of
treatment resistance is still unknown.
microRNAs (miRNAs) are evolutionarily conserved, endoge-
nous noncoding RNA of about 22 nucleotides (nt) in length
involved in protein-expression regulation at the posttranscriptional
level [1]. With the advent of miRNA expression profiling,
significant effort has been made to correlate miRNA expression
with tumor prognosis [2,3]. To date, a number of down-regulated
miRNAs found in lung cancer correlate with patient survival
[4,5,6] and with therapeutic response [7]. This finding led many
research groups to identify the molecular mechanisms responsible
for the deregulation of these miRNAs in human cancers.
Epigenetics refers to changes in gene expression that occur
without alteration in DNA sequence. There are two primary and
interconnected epigenetic mechanisms: DNA methylation of CpG
islands within promoter regions and post-translational modifica-
tion of histone tails as acetylation, phosphorylation, methylation
and ubiquitilation [8,9,10]. In addition to known genetic
mutations involved in neoplastic transformation, many evidences
suggest that cancer cells have an altered epigenetic machinery
since either DNA methylation or histone modifications are
modified compared to normal cells [11].
Recently we found both in vivo and in vitro that miR-212 was
strongly downregulated in lung cancer and that its ectopic
expression increased TRAIL (tumor necrosis factor-related
apoptosis-inducing ligand) sensitivity of lung cancer cells [12].
Since many microRNAs downregulated in cancer have been
tightly related to CpG island hypermethylation and/or alteration
in histone marks modifications [13,14,15] we wondered whether
the same modifications could be involved in miR-212 silencing in
lung cancer. Therefore, in this manuscript we investigated both
DNA methylation patterns and histone modifications of miR-212
promoter region in Calu-1 (NSCLC) and MRC5 (normal human
fibroblasts derived from fetal lung fibroblast) cells carrying
different miR-212 expression profiles. Our results show that
although the transcriptional start site of miR-212 is embedded in a
CpG island, its transcriptional inactivation in lung cancer is not
associated to DNA hypermethylation status but instead to a
change in the methylation status of histone tails linked to the
promoter region of this microRNA. Furthermore, by using tissue
specimens of lung cancer at different TNM staging we analyzed
the expression levels of miR-212 and found that its silencing is
closely associated with the severity of the disease.
Results
Expression of miR-212 in different lung cancer stages
Recently we demonstrated both in vitro and in vivo that miR-212
expression in lung cancer is down-regulated compared with
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-napolinormal lung [12]. To test whether or not its silencing correlates
with the stage of the tumor, tissue specimens were collected from
34 NSCLC-affected patients at different TNM staging (clinical
features are summarized in Table 1). We then analyzed miR-212
expression by qRT-PCR (Figure 1A). As shown, in the T1/T2
samples, the expression of miR-212 is mostly heterogeneous. On
the contrary, in the T3/T4 samples, miR-212 expression was
homogeneously down-regulated. Figure 1B shows the average of
T1/T2 samples compared to T3/T4. These data indicate that the
silencing of miR-212 is closely related to the severity of the disease.
Role of epigenetic on miR-212 expression- Using the CpG Island
Searcher program (http://www.cpgislands.com/) we found that
miR-212 locus was embedded within a CpG island. It is known that
several miRNAs are epigenetically silenced in association with CpG
island hypermethylation in cancer cells [16,17]. We thus investi-
gated whether the loss of miR-212 expression in NSCLC was
associated with DNA hypermethylation. We analyzed by bisulfite
genomic sequencing the DNA methylation status of the predicted
transcriptional start sites (TSSs) of pri-miR-212 [18,19] in Calu-1
and MRC5 cell lines that express different amounts of miR-212
(Figure 2A). As shown in figure 2B, in Calu-1 the region analyzed
was largely under-methylated. To confirm that the transcriptional
silencing of miR-212 in lung cancer was not associated with CpG
methylation, Calu-1 cells were treated with two different concen-
trations of the DNA methylation inhibitor 5-aza-29-deoxycytidine
(59Aza) as indicated. miR-212 expression was then evaluated by q-
RT-PCR (Fig. 2C–D). As shown in Figure 2C–D, upon 59Aza
treatment, miR-212 expression levels were unchanged. Taken
together these results indicate that methylation is not related to
miR-212 silencing in NSCLC.
Methylation and acetylation analysis of histones
associated to the TSS of miR-212
We then investigated whether modifications in histone proteins
could account for miR-212 downregulation in NSCLC. We
performed ChiP analysis using four antibodies against specific
histone modifications: H3K4me3 and H3K9Ac, generally associ-
ated with transcriptional active chromatin, and H3K27me3/
H3K9me2 generally associated with transcriptional inactive
chromatin. Subsequently, we compared the histone marks pattern
of the predicted miR-212 TSS both in Calu-1 and MRC5 cells. As
expected, we found significant differences in the methylation status
of H3K27 and H3K9 and in the acetylation status of H3K9
(Figure 3).Specifically,inCalu-1cellsthat expresslowlevels ofmiR-
212, TSS of miR-212 is enriched by the presenceof histone proteins
with covalent modifications involved in gene silencing (H3K27me3
and H3K9me2). On the contrary, high miR-212 expressing MRC5
cells exhibited an increase in histone modifications associated with
gene activation (H3K9Ac) compared to Calu-1 cells. Our data
suggest that epigenetic modifications on histones at miR-212 TSS
contribute to its epigenetic silencing in NSCLC.
Altered miR-212 expression in NSCLC is associated with
changes in histone modifications
The histone methyl transferase EZH2, a specific H3K27 methyl
transferase, is frequently over-expressed in human cancer [20].
Moreover, immunohistochemical analyses revealed that G9a, a
specific H3K9 methyltransferase, was highly expressed in lung
cancer tissue specimens compared to normal lung samples [21].
Based on these findings, we analyzed by q-RT-PCR the
expression levels of EZH2 and G9a enzymes in Calu-1 and
MRC5 cells. As shown in Figure 4, Calu-1 cells exhibited
increased amounts of EZH2 (A) and G9a (B) compared to
MRC5 cells. On the contrary, expression levels of H3K9 de-
acetylase HDAC did not differ in the two cells type Figure 4C.
The same results were obtained in another NSCLC cell line,
A549. As shown in figure S2, A549 cells show low levels of miR-
212 (A), upregulation of EZH2 (B) and G9a (C) and similar levels
of HDAC (D), comparing with MRC5.
In order to confirm the involvement of histone modifications in
miR-212 silencing in NSCLC, we inhibited both EZH2 expression
and HDAC activity and then analyzed the effects on miR-212
expression in Calu-1 cells. To this aim, Calu-1 cells were transfected
with EZH2-siRNA and/or treated with TSA, a specific inhibitor of
HDAC. miR-212 was then evaluated by q-RT-PCR. As expected,
either siRNA-mediated knock-down of EZH2 methylase, or TSA-
mediated inhibition of HDAC de-acetylase activity contributed to
Table 1. Clinical features of the patients.
Patients Lung tissue Stage Sex Age
1 Squamous cell
carcinoma
T1 M 80
2‘ ‘ ‘ ‘ M6 1
3‘ ‘ ‘ ‘ M8 0
4 Adenocarcinoma ‘‘ F 42
5‘ ‘ ‘ ‘ F 5 8
6‘ ‘ ‘ ‘ M6 8
7‘ ‘ ‘ ‘ F 7 2
8‘ ‘ ‘ ‘ M6 3
9‘ ‘ ‘ ‘ M6 8
10 ‘‘ ‘‘ F 61
11 Squamous cell
carcinoma
T2 M 64
12 ‘‘ ‘‘ F 56
13 ‘‘ ‘‘ M 76
14 ‘‘ ‘‘ F 48
15 ‘‘ ‘‘ M 64
16 ‘‘ ‘‘ M 75
17 ‘‘ ‘‘ M 76
18 ‘‘ ‘‘ M 64
19 ‘‘ ‘‘ M 64
20 ‘‘ ‘‘ F 74
21 ‘‘ ‘‘ F 75
22 ‘‘ ‘‘ M 74
23 ‘‘ ‘‘ M 61
24 Adenocarcinoma T3 F 55
25 ‘‘ ‘‘ M 86
26 ‘‘ ‘‘ M 74
27 ‘‘ ‘‘ M 63
28 ‘‘ ‘‘ M 64
29 Adenocarcinoma T4 F 48
30 ‘‘ ‘‘ F 61
31 ‘‘ ‘‘ F 62
32 ‘‘ ‘‘ M 64
33 Squamous cell
carcinoma
‘‘ M 61
34 ‘‘ ‘‘ F 56
doi:10.1371/journal.pone.0027722.t001
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effect was greater (four-folds) in the presence of both inhibitions.
The same effect was observed in A549 cells (Figure S2E). The
inhibition of EZH2 and HDAC produced an increase (two-folds) of
miR-212 also in MRC5 cells (Figure S2F).
In order to determine the role of G9a on miR-212 silencing, Calu-1
cells were treated with BIX01294, a specific inhibitor of G9a
methylase, in the presence or in absence of TSA. miR-212 was
evaluated by q-RT-PCR. As expected, the treatment with both
reagents, contributed to increase miR-212 expression levels up to 5
folds (Figure 4E). Taken together these results suggest that the
upregulation of EZH2 and G9a enzymes in lung cancer contributes to
increase histone methylation and thus to decrease miR-212 expression
levels.When used at the same time, siEZH2/TSA or BIX01294/TSA
produced greater effects on miR-212 expression compared to the
single incubation. Thus, it is possible to speculate that H3K27me3 or
H3K9me2-mediated silencing machinery requires HDAC activity, as
reported previously by Lachner M et al [22].
Effects of inhibition of EZH2, G9a and HDAC on histone
proteins
Based on this findings, we wondered whether the inhibition of
EZH2, G9a and HDAC enzymes in Calu-1 cells may cause a
change in the H3K27me3, H3K9me2 and H3K9Ac histone marks
pattern at the TSS of miR-212 affecting thus miR-212 expression
levels. To this aim, Calu-1 cells were treated with siEZH2 and TSA
and ChiP analyses were performed using H3K27me3 and H3K9Ac
antibodies, respectively. Interestingly, inhibiting both methylase
(EZH2) and de-acetylase (HDAC), strongly increased the acetyla-
tionof H3K9 and significantlydecreased themethylationofH3K27
of miR-212 TSS compared with untreated cells (Figure 5A). These
results correlate with the up-regulation of miR-212 in the same
experimental condition (compare Figure 4D with Figure 5A). In
addition, Calu-1 cells were treated with BIX01294 and TSA
inhibitors and ChiP analyses were carried using H3K9me2 and
H3K9Ac antibodies, respectively. As expected, we found that
inhibiting the catalytic activity of either methylase (G9a) or de-
acetylase(HDAC),stronglydecreasedthemethylationofH3K9 and
significantly increased the acetylation of H3K9 on miR-212 TSS
compared with untreated cells (Figure 5B). Taken together, these
results strongly demonstrate that specific changes in histone
modifications determine miR-212 silencing in NSCLC.
Effect of inhibition of EZH2, G9a and HDAC on apoptosis
in Calu-1 cells
It is known that inhibition of HDAC by TSA, induces cell cycle
arrest and apoptosis in different cancer cells as glioma, bladder
cancer, leukemic cells and SCLC [23,24]. Besides, in human
Figure 1. Expression of miR-212 in human lung cancer tissues specimens. (A) Total RNA extracted from tissue specimens collected from 34
NSCLC-affected individuals at different TNM staging (T1-T2-T3-T4) was used to analyze miR-212 expression by Real-Time PCR. (B) Mean 6 SD of miR-
212 expression of pool T1/T2 vs T3/T4. Error bars indicate SD. *p,0.05, by t test. As shown, in the T1/T2 staging the expression of miR-212 is clearly
heterogeneous while in the T3/T4 staging the miR-212 expression is strongly silenced and correlates with severity of disease.
doi:10.1371/journal.pone.0027722.g001
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27722Figure 2. Analysis of DNA methylation status of the miR-212 promoter region. (A) Expression analysis of miR-212 in NSCLC (Calu-1) and
normal human fibroblasts derived from fetal lung (MRC5) by Real- Time PCR. (B) Bisulfite genomic sequencing analyses of the miR-212 CpG island in
Calu-1 and MRC5 cells. Eight single clones are represented for each sample. Black and white squares represent methylated and unmethylated CpG
respectively, and each vertical bar illustrates a single CpG. (C) Expression analysis of mature miR-212 by Real-Time PCR in Calu-1 cells in absence
(control) or in presence of 1 mM (left panel) and 5 mM (right panel) of DNA methylation inhibitor 5-aza-29-deoxycytidine (5-Aza-2dC), as indicated. In
NSCLC, DNA hypermethylation of CpG island is not detected suggesting that this epigenetic modification is not responsible of miR-212 silencing.
Means 6 SD of four independent experiments in triplicate are given.
doi:10.1371/journal.pone.0027722.g002
Figure 3. Transcriptional silencing of miR-212 in lung cancer cells is associated with histone modifications. ChiP and Real-Time PCR
were used to study, in Calu-1 and MRC5 cells, histone modifications in the promoter region of miR-212 using antibodies directed against H3K4me3,
H3K27me3, H3K9me2 and H3K9Ac. A negative control antibody (IgG) was included in the ChiP assay. Means 6 SD of four independent experiments
in triplicate are given.
doi:10.1371/journal.pone.0027722.g003
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induced apoptosis and G1 arrest, respectively [25]. Our recent
findings demonstrated that ectopic expression of miR-212 sensitizes
Calu-1 cells to TRAIL-induced apoptosis [12]. We therefore verified
whether the inhibition of EZH2, G9a and HDAC enzymes may
increase TRAIL sensitivity of Calu-1 cells. To this aim, Calu-1 cells
were treated with BIX01294 and TSA to inhibit G9a and HDAC
enzymes and apoptosis was evaluated by western blot analysis of
caspase-8 activation upon TRAIL treatment. As reported in
Figure 6A, caspase-8 is clearly activated in presence of G9a or
HDAC inhibition. Moreover, caspase-8 activation further increases
in the presence of both enzymes inhibition, condition that correlates
with up-regulation of miR-212 (compare Figure 6A with Figure 4E).
For the same purpose, apoptosis induction was evaluated by
inhibiting the EZH2 and HDAC enzymes by siEZH2 and TSA.
Differently from the results obtained above, caspase-8 was activated
only in presence of HDAC inhibition and not in presence of EZH2
knock-down (Figure 6B). To further confirm these results we
performed Annexin V apoptosis assay (Figure S1).
Discussion
MicroRNAs are small non-coding RNAs molecules that
function as endogenous posttranscriptional silencers of target
genes and are important regulators of different cellular processes
including apoptosis [26,27]. Defects in the apoptotic program may
contribute to treatment resistance and tumor progression, and
may be caused by deregulated expression of anti-apoptotic
molecules. The number of discovered microRNAs and their
targets grow quickly indicating their essential role in maintaining
gene expression profile. We recently demonstrated for first time
the pro-apoptotic role of miR-212 in lung cancer. Specifically, we
found that miR-212 was able to target the anti-apoptotic protein
PED upregulated in lung cancer [28] suggesting that its action
may contribute to tumor suppression since it negatively inhibits a
molecule involved in apoptosis resistance [12]. Moreover,
analyzing human tissues specimens of normal and lung cancer
we found that the up-regulation of PED protein in lung cancer
tissues was correlated with miR-212 silencing and in vitro with
apoptosis resistance. Nevertheless, the relationship between miR-
212 silencing with progression and severity of disease was still
unknown. To this end, using tissue specimens from NSCLC-
affected patients in the T1-T2-T3 and T4 staging, we found that
in T1/T2 the expression of miR-212 was heterogeneous whereas
in the T3/T4 all samples analyzed showed miR-212 downregu-
lation. These results suggest that silencing of miR-212 in lung
cancer is closely related to the severity of the disease. However, the
Figure 4. Role of EZH2 and G9a enzymes in histone methylation pattern and in miR-212 expression levels in NSCLC. (A) Expression
analysis of EZH2, (B) G9a and (C) HDAC enzymes by Real-Time PCR in Calu-1 and MRC5 cells. (D) Expression analysis of mature miR-212 in Calu-1 cells
untreated (2) or treated (+) with siEZH2 and TSA inhibitor or (E) with TSA and BIX01294 (BIX) inhibitors. (D) Calu-1 cells were transfected with specific
EZH2-siRNA for 24 hours. Then, the cells were incubated with 100 ng/ml of TSA for 24 hours and miR-212 expression was evaluated by qRT-PCR.
Down-regulation of EZH2 expression after siEZH2 transfection was evaluated by western blotting using anti-EZH2 antibody. To confirm equal loading
the membrane was immunoblotted with anti-b-actin antibody. (E) Calu-1 cells were treated with 100 ng/ml of TSA for 16 or 24 hours in presence or
in absence of 10 mM of BIX for 16 hours and miR-212 expression was evaluated by Real-Time PCR. These results suggest that in Calu-1 cells the
upregulation of EZH2 and G9a enzymes contributes to increase histone methylation and thus to decrease miR-212 expression levels. Means 6 SD of
four independent experiments in triplicate are given.
doi:10.1371/journal.pone.0027722.g004
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cancer are still unknown, and this was the focus of our study.
Several studies have analyzed the expression of miR-212 in
different cells types in order to determine its role in tissue-specific
physiology. miR-212 expression levels were found higher in
forebrain regions of the adult rat brain [29] strongly downregu-
lated in the tissues of fetuses with anencephaly [30] and, in
association with miR-132, higher in hippocampal neurons.
Moreover, miR-212 has been described as involved in normal
dendrite maturation in newborn neurons in the adult hippocam-
pus [31].
To date, few reports show an involvement of miR-212 in cancer
but all of them indicate that this miRNA is deregulated in different
human cancer. In particular, miR-212 expression decreases in
both gastric carcinoma (GC) cells and in human primary GC
tissues suggesting that its downregulation may be related to gastric
carcinogenesis through its target genes such as methyl-CpG-
binding protein [32]. In pancreatic adenocarcinoma tissues miR-
212 is over-expressed and targets the retinoblastoma tumor
suppressor [33] Using microarray analysis thirteen miRNA,
including miR-212, were found significantly overexpressed in oral
tumors [34]. In addition, increased expression of HB-EGF
(heparin-binding EGF-like growth factor) due to down-regulation
of miR-212 in head and neck squamous cell carcinoma (HNSCC)
has been described as a possible mechanism of cetuximab
resistance [35].
Cancer cells have a specific epigenome. In the last decade many
studies have shown that the aberration of epigenetic marks such as
DNA methylation in CpG islands and covalent modifications of
histone proteins involved in chromatin organization, contribute
significantly to malignant transformation. On the other hand, it
has been demonstrated that the expression of miRNAs can be
affected by epigenetic changes. In bladder tumors it was found that
miR-127 is silenced by promoter methylation and its expression
could be restored by hypomethylating agents [16]. Lujambio et al
treated several cancer cell lines derived from lymphonode
metastases with DNA demethylating agents and using miRNA
expression microarray analysis found that miR-148a, miR-34b/c,
Figure 5. Inhibition of EZH2, G9a and HDAC enzymes cause a change in the histone marks pattern at the TSS of miR-212. ChiP and
qRT-PCR were used to analyze, in Calu-1 cells, histone modifications at the predicted miR-212 TSS (A) in absence (scrb) or in presence of TSA and
siEZH2, and (B) in absence (scrb) or in presence of TSA and BIX inhibitors, respectively. (A–B) Calu-1 cells were treated in presence of the indicated
inhibitors as described in the legend of figure 4. The results indicate that the histone modification catalyzed by EZH2, G9a and HDAC enzymes sites
are involved in miR-212 silencing in NSCLC. Means 6 SD of four independent experiments in triplicate are given.
doi:10.1371/journal.pone.0027722.g005
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methylation [36]. Similarly, in colon cancer cells miR-124a
silencing was associated with CpG island hypermethylation [17].
Using bioinformatics programs we found a CpG island in the
promoter of miR-212 gene. Aberrant methylation of the promoter
CpG island region is a common epigenetic mechanism for
transcriptional silencing. Therefore, we measured the effects of
AZA on the transcriptional regulation of miR-212 in Calu-1 cells
that express low levels of miRNA. Surprisingly, although the
promoter element of miR-212 resides within a CpG island we
found that Calu-1 treatment with specific inhibitor for DNA
methylase did not change the expression of miR-212.
Epigenetic silencing in mammalian cells is mediated by at least
two distinct histone modifications: H3K27 trimethylation and
H3K9 dimethylation [37]. The relationship between DNA
hypermethylation and these histone modifications is not com-
pletely understood. Interestingly, Kondo et al showed a newly
identified epigenetic aspect of gene deregulation in cancer cell
[38]. They found that up to 5% of the genes on the CpG
microarray were silenced in cancer cells by marked elevation in
H3K27me3 associated with relatively low levels of promoter DNA
methylation. In addition, it was recently found that miR-22
silencing involves accumulation of H3K27me3 independent of
promoter DNA methylation in acute lymphoblastic leukemia [39].
These data suggest that H3K27me3 is an alternate mode of gene
silencing in cancer independent from DNA methylation. Consis-
tent with these recent studies we performed ChIP analysis in lung
cancer cells (Calu-1) and in normal human fibroblasts derived
Figure 6. Inhibition of G9a and HDAC enzymes induced TRAIL sensitivity. (A) Calu-1 cells were treated in absence (2) or in presence (+)o f
100 ng/ml of TSA and/or 10 mM of BIX, as previously described, then the cells were incubated with 1 ng/ml of Super-Killer TRAIL for 3 hours. Lysates
were analyzed by western blotting with anti-caspase-8 antibody. Cleavage of caspase-8 was more evident in Calu-1 cells treated in presence of both
inhibitors. (B) Calu-1 cells were transfected with siEZH2 and treated in absence or in presence of 100 ng/ml TSA, as previously described, then cells
were incubated with 1 ng/ml of TRAIL. b-actin antibody was used as loading control.
doi:10.1371/journal.pone.0027722.g006
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27722from fetal lung (MRC5) to investigate changes of histone
modifications associated with transcriptional active and/or
inactive chromatin of miR-212 promoter region. As expected,
we found increasing amounts of H3K27me3 and H3K9me2
(covalent modification involved in gene silencing) in the promoter
region of miR-212 in Calu-1 compared to MRC5 cells and
increasing amounts of H3K9Ac (covalent modification involved in
gene expression) in the promoter region of miR-212 in MRC5
compared to Calu-1 cells. Moreover, we found that inhibitors of
the enzymes involved in histone modifications, i.e. siEZH2, TSA
and BIX01294, were able to up-regulate miR-212 expression in
Calu-1 cells. Taken together these results indicate that, although
the DNA hypermethylation appears to be essential for gene
silencing, the transcriptional silencing of miR-212 in NSCLC
involves H3K27me3/H3K9Ac or H3K9me3/H3K9Ac-associat-
ed histone modification independent of promoter DNA methyl-
ation.
We also tested the effects on TRAIL-induced cells death in
NSCL of the different inhibitors.
In fact, our recent findings demonstrated that ectopic expression
of miR-212 sensitizes Calu-1 cells to TRAIL-induced apoptosis
[12]. Our data show that TRAIL sensitivity of Calu-1, assessed by
the western blot analysis of caspase 8 and by FACS analysis, was
greater increased by the inhibition of G9a then that of EZH2. The
absence of the effect of siEZH2 on TRAIL sensitivity in Calu-1
cells may be ascribed to different mechanisms. It is possible that: (i)
the 70% reduction of EZH2 obtained by the treatment with the
specific siRNA is not sufficient to increase TRAIL response (ii)
EZH2 knock-down, besides miR-212, may regulate other
important signaling molecules involved in TRAIL signaling (iii)
to regulate TRAIL- signaling pathway, EZH2 may need the
concomitant HDAC inhibition that may modulate the expression
levels of different molecules involved in TRAIL response. Further
studies are needed to explore these different hypothesis.
In conclusion, this study shows that miR-212 silencing is
correlated to the severity of the disease since it is significantly
down-regulated in T3/T4 staging rather than in T1/T2 staging
and that its silencing in lung cancer is associated to histone
modifications rather than DNA hypermethylation.
Materials and Methods
Cell culture
Calu-1 (NSCLC) and MRC5 (normal human fibroblasts
derived from fetal lung fibroblast) cells were grown in DMEM.
Media were supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 2 mM L-glutamine and 100 U/ml penicillin/
streptomycin.
Lung cancer samples
A total of 34 Formalin-Fixed, Paraffin-Embedded (FFPE) tissue
samples consisting of both adeno and squamous cell carcinomas
were collected from the archives of the Department of Pathology,
University Hospital of Kuopio, Finland. Permission to use the
material was obtained from the National Supervisory Authority for
Welfare and Health of Finland and the study was accepted by the
ethical committee of the Northern Savo Hospital District, Kuopio,
Finland.
RNA extraction and Real-Time PCR
Cell culture. Total RNAs (miRNA and mRNA) of Calu-1
and MRC5 cells was extracted using miRNeasy mini Kit (Qiagen)
according to the manufacturer’s protocol. Tissue specimen: Total
RNA (miRNA and mRNA) from FFPE tissue specimens was
extracted using RecoverAll Total Nucleic Acid isolation Kit
(Ambion) according to the manufacturer’s protocol. Reverse
transcription of total miRNA and mRNA was performed using
500 ng (from cell culture) or 50 ng (from FFPE tissue specimens) of
total RNA/sample by miScript Reverse Transcription Kit
(Qiagen) according to the manufacturer’s protocol. Quantitative
analysis of miR-212, EZH2, G9a and HDAC were performed by
RealTime PCR using miScript SYBR Green PCR Kit (Qiagen)
according to the manufacturer’s protocol. As internal reference we
used RNU5A and GAPDH. EZH2 except (Fw: CCACCAT-
TAATGTGCTGGAA Rv: TTCCTTGGAGGAGTATCCACA)
all primers used were purchased from Qiagen. The reaction for
detection of miRNA and mRNAs was performed as previously
described [12]. Experiments were carried out in triplicate for each
data point, and data analysis was performed by using software
(Bio-Rad).
DNA Methylation analysis
The CpG Island Searcher program (http://www.cpgislands.
com/) was used to establish that miR-212 coding region is
embedded in a CpG island. DNA methylation status was
evaluated by sequencing analysis of bisulfite-modified genomic
DNA included in the corresponding CpG island. Bisulfite
treatment induces chemical conversion of unmethylated cytosine
into uracil leaving methylated cytosine unchanged. Genomic DNA
was modified using EZ DNA Methylation Kit (Zymo Research)
according to the manufacturer’s protocol. Bisulfite-treated DNA
was used as template to amplify the region including miR-212
transcription start site on reverse strand using the following
primers: 59-TTTTGGGTGGTATTTGAATTTT-39;R V5 9-
CCCCTCCTCAATTCCTAAA-39. Then, PCR products were
cloned into p-GEM-T Easy Vector System II (Promega), and eight
independent clones from each sample were sequenced.
Chromatin Immunoprecipitation analysis
Chromatine Immunoprecipitation assays were carried out using
Lowcell ChIP Kit (Diagenode) according to the manufacturer’s
protocol. Briefly, the cells were treated with 1% formaldehyde, a
cross-linking agent, for 10 min. Then, chromatin was sheared with
a Bioruptor (Diagenode) to an average length of 0.4–0.8 kb.
Sheared chromatin was immunoprecipitated for 16 hours at 4uC
using the following antibodies: anti-thrimethyl-K4 histone H3,
anti-thrimethyl-K27 histone H3, anti-dimethyl-K9 histone H3 and
anti-acetyl-K9 histone H3 (Diagenode). In addition, 1/100 of the
solution collected before adding the antibody was used as an
internal control for the amount of input DNA. Real-Time PCR
was carried out in 25 ml containing 5 ml of the immunoprecipi-
tated DNA, 12.5 ml SYBR green PCR Master mix (Qiagen) and
150 nM of specific primers (FW 59-GGAGTCCAGCTTCC-
TCTCCT-39;R V5 9-GCTCCTGGGGGTCTTCAC). The PCR
protocol entailed 10 min at 95uC and 40 cycles of 15 sec at 94uC
and 1 min at 60uC. Experiments were carried out in triplicate for
each data point, and data analysis was performed by using
software (Bio-Rad).
Small Interfering RNA Transfection
The siRNA duplex for negative control and EZH2 mRNA
(Dharmacon) were transiently transfected for 48 h in Calu-1 cells
using LIPOFECTAMINE 2000 (Invitrogen), according to the
manufacturer’s instructions. Then, expression values of EZH2 and
miR-212 levels were evaluated by Real-Time PCR and western
blot analysis. Experiments were carried out in triplicate for each
data point.
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Cells were washed twice in ice-cold PBS, and lysed in JS buffer
(50 mM HEPES pH 7.5 containing 150 mM NaCl, 1% Glycerol,
1% Triton 6100, 1.5 mM MgCl2, 5 mM EGTA, 1 mM
Na3VO4, and 16protease inhibitor cocktail). Protein concentra-
tion was determined by the Bradford assay (Biorad) using bovine
serum albumin as standard, and equal amounts of proteins were
analyzed by SDS-PAGE (12.5% acrylamide). Gels were electro-
blotted onto polyvinylidene difluoride membranes (Millipore,
Bedford, MA). For immunoblot experiments, membranes were
blocked for 1 hr with 5% non-fat dry milk in Tris Buffered Saline
(TBS) containing 0.1% Tween-20, and incubated at 4uC over
night with primary antibody. Detection was performed by
peroxidase-conjugated secondary antibodies using the enhanced
chemiluminescence system (Amersham-Pharmacia Biosciences).
Primary antibodies used were: anti-EZH2 (Cell Signaling), anti-
caspase 8 (Cell Signaling), and anti-bactin (Sigma).
Cell death assessment by Annexin V staining
Cell death was assessed by annexin V and FACS analysis as
previously described [12]. Briefly, cells were seeded at 12610
4 cells
per 60-mm dish, grown overnight in 10% FBS/DMEM, washed
with PBS, then transfected with siEZH2 or a scrambled sequence.
After 24 hours cells were treated with of 100 ng/ml of TSA for
24 hours and/or 10 mM of BIX for 16 hours. Following
incubation, cells were washed with cold PBS and removed from
the plates by very mild trypsinization conditions (0.01% trypsin/
EDTA). The resuspended cells were washed with cold PBS and
stained with FITC-conjugated annexin V antibody and propidium
iodide (PI) according to the instructions provided by the
manufacturer (BD Pharmigen, San Diego, CA). Cells were then
subjected to flow cytometric analysis. The percentage of apoptosis
indicated was corrected for background levels found in the
corresponding untreated controls.
Statistical analysis
Continuous variables are expressed as mean values 6 standard
deviation (SD). One and two-tailed student’s t-test were used to
compare values of test and control samples. p,0.05 was
considered significant.
Supporting Information
Figure S1 Effects of epigenetic modifications on cell
death. Calu-1 cells were treated in absence (2) or in presence (+)
of 100 ng/ml of TSA and/or 10 mM of BIX, or transfected with
siEZH2 and treated in absence or in presence of 100 ng/ml TSA,
as previously described. The cells were incubated with 1 ng/ml of
Super-Killer TRAIL for 3 hours. Apoptosis was evaluated with
Annexin V staining. A representative dot blot is shown (A). Means
6 SD of four independent experiments in triplicate are given (B).
(EPS)
Figure S2 Effects of EZH2 and HDAC inhibition on miR-
212 expression in A549 and MRC5 cell lines. Expression
analysis of miR-212 (A), EZH2 (B), G9a (C) and HDAC (D)b y
Real-Time PCR in A549 and MRC5 cells. Expression analysis of
mature miR-212 in A549 (E) and MRC5 (F) cells untreated (2)o r
treated (+) with siEZH2 and TSA. Cells were transfected with
specific EZH2-siRNA for 24 hours, then incubated with 100 ng/
ml of TSA for 24 hours and miR-212 expression was evaluated by
qRT-PCR. Down-regulation of EZH2 expression after siEZH2
transfection was evaluated by western blotting using anti-EZH2
antibody. To confirm equal loading the membranes were
immunoblotted with anti b-actin antibody. Means 6 SD of four
independent experiments in triplicate are given.
(EPS)
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